DARBITOP 100 VIAL

About

Darbitop 100 VIAL contains darbepoetin alfa, an erythropoiesis-stimulating agent (ESA) that is a recombinant human erythropoietin analog. It functions by stimulating erythropoiesis (red blood cell production) in the bone marrow, mimicking the action of endogenous erythropoietin. This medication is primarily used to treat anemia associated with chronic kidney disease (CKD) in both dialysis and non-dialysis patients, and anemia in cancer patients receiving myelosuppressive chemotherapy.

Darbepoetin alfa has a longer half-life compared to epoetin alfa, allowing for less frequent dosing, which can improve patient convenience and adherence. Its therapeutic goal is to increase and maintain hemoglobin levels, thereby reducing the need for red blood cell transfusions and improving the quality of life for anemic patients. Careful monitoring of hemoglobin levels, blood pressure, and potential cardiovascular risks is crucial during treatment.

Uses

• Anemia associated with chronic kidney disease (CKD).
• Anemia in cancer patients receiving myelosuppressive chemotherapy.
• Reduction of allogeneic red blood cell transfusions in surgery.
• Management of anemia in HIV-infected patients on zidovudine.

Directions For Use

Administer intravenously or subcutaneously as directed by a healthcare professional. Dosage and frequency depend on the patient's condition and hemoglobin levels.

Benefits

• Increases red blood cell count and hemoglobin levels.
• Reduces the need for blood transfusions.
• Improves quality of life for anemic patients.
• Longer half-life allows for less frequent dosing.
• Effective in both CKD and chemotherapy-induced anemia.
• Helps manage fatigue associated with anemia.

Side Effects

• Hypertension
• Headache
• Arthralgia
• Peripheral edema
• Nausea
• Diarrhea
• Injection site pain
• Thrombosis (DVT, PE)
• Stroke
• Tumor progression (in some cancers)
• Pure red cell aplasia (rare)
• Seizures

Safety Measures

• Alcohol - No direct interaction with alcohol. However, excessive alcohol intake can worsen anemia or liver function, which may complicate underlying conditions.
• Pregnancy - Use during pregnancy should only be considered if the potential benefit outweighs the potential risk to the fetus. Consult a physician before use.
• Breastfeeding - It is unknown if darbepoetin alfa is excreted in human milk. Use with caution and consult a healthcare provider.
• Liver - Use with caution in patients with severe hepatic impairment. Liver function should be monitored, though dose adjustment is not typically required.
• Kidney - Primarily used in patients with chronic kidney disease. Hemoglobin levels and kidney function should be closely monitored to avoid adverse events.
• Lung - Caution is advised in patients with pre-existing pulmonary hypertension, as ESAs may exacerbate this condition. Monitor for respiratory symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.